Skip to content

AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT

Langue and Imaging-integrated Foundation Model for Gastric Cancer Detection and Staging Via Contrast-Enhanced CT: a Multicenter Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07250347
Enrollment
8000
Registered
2025-11-26
Start date
2025-08-01
Completion date
2028-12-30
Last updated
2025-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer Patients Undergoing Gastrectomy, Gastric Cancer Stage

Keywords

Gastric cancer, stage, artificial-intelligence, detection, contrast-enhanced CT

Brief summary

Accurate preoperative assessment of gastric cancer stage guides eligibility for endoscopic resection, extent of gastrectomy and lymphadenectomy, selection for neoadjuvant therapy, and use of staging laparoscopy. Contrast-enhanced CT (CECT) is guideline-endorsed for initial staging, yet performance varies across institutions and readers. This study will evaluate an artificial-intelligence (AI) system that analyzes routine CECT to detect gastric cancer and assign four-class T stage (T1-T4) and N stage (N0-N3) .

Detailed description

Adults with confirmed gastric cancer undergoing pre-treatment CECT will be enrolled. The AI analysis will be applied to clinically acquired images. Radiologist interpretations with and without AI support will be collected in a prespecified reader study. The reference standard will include surgical pathology, supplemented by clinical follow-up when applicable. The primary outcome is detection performance, diagnostic performance of the AI for four-class staging (e.g., accuracy and area under the receiver operating characteristic curve). Secondary outcomes include the effect of AI assistance on reader accuracy and interpretation time, inter-reader agreement, and cross-site reproducibility.

Interventions

DIAGNOSTIC_TESTCT scan

preoperative contrast-enhanced CT

Sponsors

Jiangsu Cancer Institute & Hospital
CollaboratorOTHER
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
CollaboratorUNKNOWN
Peking University First Hospital
CollaboratorOTHER
The First Affiliated Hospital with Nanjing Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. pathologically confirmed gastric cancer; 2. preoperative contrast-enhanced CT performed; 3. no evidence of distant metastasis on baseline staging; 4. curative-intent management with complete postoperative histopathology.

Exclusion criteria

1. prior treatment before surgery; 2. non-diagnostic or poor-quality CT precluding evaluation.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic performance of the AI model for staging3 yearsThe primary outcome is the diagnostic accuracy of the AI system for four-class T staging (T1-T4) and N staging (N0-3) based on contrast-enhanced CT. The AI performance will be assessed using accuracy, area under the receiver operating characteristic curve (AUC), and micro-AUC for internal and external cohorts.

Secondary

MeasureTime frameDescription
Reader Accuracy with AI Support3 yearsThis outcome measures the accuracy of radiologists in classifying gastric cancer stagewhen aided by the AI system compared to manual classification without AI assistance. Accuracy will be compared between different radiologist experience levels.
Survival time3 yearsCalculate the survival time of gastric cancer patients from the point of diagnosis and treatment initiation.

Countries

China

Contacts

Primary ContactZhang Yudong, PHD, MD
zhangyd3895@njmu.edu.cn+8618251966069
Backup ContactQiong Li
njmu_lq@163.com+8618351977281

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026